Skip to Main Content

Paper Details

BRAF<sup>οβ3-αC</sup> in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.
Sci Adv
0
2023
BRAF, BRAF mutants, BRAF oncoproteins, CDC37, HSP 90, HSP90, RAF, RAFi, amino acids, aromatic amino acids, cell lines, dabrafenib, exon 12, in-frame deletion mutants, naporafenib, patient, tumor, tumors
Author NameAffiliation
Daniel H??bschmann
Daniel H??bschmannHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Daniel H??bschmannNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Daniel H??bschmann
Daniel H??bschmannNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Daniel H??bschmannHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Steven GallingerOntario Institute for Cancer Research
Steven GallingerPrincess Margaret Cancer Centre, University Health Network
Stefan Fr??hlingNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Stefan Fr??hling
  • 1 - 10

Datasets

Release 1.2